---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-087029"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:53:13.986047+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Unicycive reports Q3 net loss of $4.4M; FDA alignment on OLC NDA path

## Summary
- Net loss $4.4M ($0.13/share) vs $5.6M ($0.37/share) in Q3 2022; R&D expenses $3.4M, down from $4.8M.
- Reached agreement with FDA on data package for OLC NDA; pivotal trial of 60 patients expected by year-end, topline data mid-2024.
- Cash $14.3M expected to fund into H2 2024 including pivotal trial and topline data.
- Appointed Dr. Sara Kenkare-Mitra to Board of Directors; she has experience with 100+ IND filings and 11 drug approvals.
- No licensing revenue in Q3 vs $1.0M in prior period due to 2022 upfront payment.

## SEC filing metadata
- accession: 0001213900-23-087029
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390023087029/0001213900-23-087029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390023087029/ea188373-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-087029
- JSON: https://secwatch.observer/filing/0001213900-23-087029.json
- Plain text: https://secwatch.observer/filing/0001213900-23-087029.txt

## Key facts
- Earnings Releases
  Unicycive Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue $0, EPS $0.13 per share of common stock.
  - Period: third quarter ended September 30, 2023
  - Revenue: $0
  - EPS: $0.13 per share of common stock
  - Result: reported results
  source text: compared to five other commercially available phosphate binders. Financial Results for the Third Quarter Ended September 30, 2023 Licensing Revenues: Licensing revenues were $0 compared to $1.0 million for the same period in 2022, due to an upfront payment for a licensing agreement entered into with Lee’s Pharmaceutical (HK) Limited in July 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023087029/0001213900-23-087029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.